anti-PD-L1

Overview

Anti-PD-L1 (Programmed Death-Ligand 1) refers to a class of therapeutic agents designed to inhibit the interaction between PD-L1 and its receptor PD-1 (Programmed Cell Death Protein 1). This interaction is a critical mechanism of immune evasion employed by various tumors, allowing them to escape detection and destruction by the immune system. By blocking PD-L1, these agents enhance T-cell activation and proliferation, thereby promoting anti-tumor immune responses. Anti-PD-L1 therapies, such as durvalumab and atezolizumab, have revolutionized cancer treatment, particularly in malignancies like melanoma, lung cancer, and bladder cancer.

Focus of Latest Publications

Recent studies have explored the efficacy and mechanisms of anti-PD-L1 therapies in various cancer contexts. For instance, a study published in Human Vaccines & Immunotherapeutics (PMID: 41866914) investigated a novel bifunctional fusion protein targeting both anti-PD-L1 and TGF-β in recurrent cervical cancer. This research aimed to identify patient sensitivity to these therapies and elucidate underlying mechanisms of action.

In another study featured in Biomaterials (PMID: 41633299), researchers developed genetically engineered nanoparticles that enhance immune responses against recurrent metastatic triple-negative breast cancer through dual PD-L1 targeting and checkpoint inhibition. This highlights the potential of combining anti-PD-L1 therapies with innovative delivery systems to improve therapeutic outcomes.

Moreover, the role of PD-L1 in immune escape was further elucidated in a study on gallbladder cancer (PMID: 41791643), where the ERRα-ETV5 signaling axis was shown to upregulate PD-L1 expression, contributing to immune evasion. This finding underscores the importance of understanding the regulatory pathways influencing PD-L1 expression in developing effective immunotherapies.

Other studies have examined the limitations of PD-1/PD-L1 inhibitors, noting issues such as low response rates and drug resistance (PMID: 41973150). Research has also indicated that factors like the tumor microenvironment and immune cell interactions significantly influence PD-L1 expression and therapeutic efficacy (PMID: 41963297). For example, the expression of PD-L1 was correlated with immune cell fractions in colorectal cancer, suggesting that immune context plays a vital role in treatment response (PMID: 41872462).

Additionally, novel approaches, such as the use of CRISPR-Cas12a technology and machine-learning models, have been employed to enhance the understanding of PD-L1 interactions and predict responses to immunotherapy (PMID: 41925960, 41943281). These advancements may pave the way for more personalized treatment strategies.

Key Publications

• Apr Faecalibacterium prausnitzii enzyme reprograms PD-L1 trafficking and sensitizes colorectal cancer to immunotherapy in mice. (Nature microbiology, 2026, PMID 41998161): "This leads to Rab11a degradation and the disruption of PD-L1 trafficking to reduce the inhibition of T-cell responses."
• Apr Assessment of Programmed Cell Death Ligand-1 Expression in Oral Potentially Malignant Disorders and Tumor-Free Surgical Margins of Oral Squamous Cell Carcinoma: Protocol for a Retrospective Cross-Sectional Study. (JMIR research protocols, 2026, PMID 41990236): "Programmed cell death ligand-1 (PD-L1), an immune checkpoint molecule, contributes to tumor immune evasion and has been implicated in cancer progression."
• Apr The emerging landscape of lncRNAs in gastric cancer immunity: From immune escape to ferroptosis and metabolic reprogramming. (Biochemical and biophysical research communications, 2026, PMID 41747446): "Recent studies have revealed that lncRNAs modulate PD-L1 expression, govern the recruitment and polarization of immunosuppressive cells such as regulatory T cells and M2 macrophages, and alter cytokine and chemokine signaling to create immune-tolerant niches."
• Apr Self-adjuvanting α-helical polypeptide simultaneously delivers neoantigen mRNAs and activates dendritic cells to eradicate tumors. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 41984833): "We also observed the upregulated expression of Programmed Death-1 (PD-1) by intratumoral CD8+ T cells and PD-L1 by 4T1 tumor cells after polyplex treatment and further demonstrated the synergistic effect between polyplex vaccine and anti-PD-1 therapy."
• Apr Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression. (Cancer research, 2026, PMID 41534088): "...boosting immune resistance in gastric cancer by enhancing programmed cell death ligand 1 (PD-L1) expression."
• Apr Clinical Characteristics and Management of PD-1/PD-L1 Inhibitor-Induced secondary Adrenal Insufficiency. (Endocrine connections, 2026, PMID 41973678): "Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors significantly improve outcomes in multiple malignancies; however, they can induce immune-related endocrine adverse events, such as secondary adrenal insufficiency (SAI), a rare but potentially severe complication."
• Apr Ratio-Tunable Dual-Peptide and Ultrasound-Assisted Nanoplatform for Enhancing Personalized Antitumor Immunotherapy. (Advanced materials (Deerfield Beach, Fla.), 2026, PMID 41979280): "BiNPs promote lysosomal internalization and degradation of CD47 and PD-L1 through a lysosome targeting chimera inspired process."
• Apr Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy. (BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2026, PMID 41973150): "Programmed Cell Death Protein 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) inhibitors have revolutionized cancer immunotherapy but are limited by low response rates and drug resistance."
• Apr Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial. (Journal for immunotherapy of cancer, 2026, PMID 41963080): "Immune checkpoint inhibitors achieve high response rates in relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL), but few treatment options are available for patients who experience failure after PD-1/PD-L1 blockade."
• Apr Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond. (Signal transduction and targeted therapy, 2026, PMID 41963297): "...such as indoleamine 2,3-dioxygenase (IDO), PD-L1, arginase-1 (ARG1), and transforming growth factor-β (TGF-β)..."